Acrux Ltd has released a press release.
ASX Small and Mid Cap Conference presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from Acrux
- FY24 Full Year Results - Investor Presentation
- Appendix 4E and FY24 Full Year Statutory Accounts
- FDA Approval received for Dapsone Gel, 7.5%
- Quarterly Activities Report and Appendix 4C - June 2024
- Acrux presentation to Bioshares, 18th Biotech Summit
Later from Acrux
- FY24 R&D Tax Incentive rebate received
- AGM Presentation
- Trading Halt
- FDA Approval - Nitroglycerin Ointment
- Share Placement successfully concluded and SPP launched
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux